Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize

Nature Communications

Volumn 7, Issue , 2016, Pages

  Adams, Stephen R ^a   Yang, Howard C ^b   Savariar, Elamprakash N ^a   Aguilera, Joe ^b   Crisp, Jessica L ^a   Jones, Karra A ^c   Whitney, Michael A ^a   Lippman, Scott M ^d,e   Cohen, Ezra E W ^d,e   Tsien, Roger Y ^a,e   Advani, Sunil J ^b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN B; CELL SURFACE RECEPTOR; CETUXIMAB; CISPLATIN; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MALEIMIDE DERIVATIVE; MAYTANSINOID; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG; VEDOTIN; AMINOBENZOIC ACID DERIVATIVE; AURISTATIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MAYTANSINE; OLIGOPEPTIDE; RADIOSENSITIZING AGENT; TRASTUZUMAB EMTANSINE; TUBULIN MODULATOR;

ANTIBODY; CANCER; DRUG; GENE EXPRESSION; PROTEIN; TUMOR; ULTRAVIOLET RADIATION;

ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CELL SURVIVAL; CELL VIABILITY; CHEMORADIOTHERAPY; CLONOGENESIS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ESOPHAGUS CANCER; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; IONIZING RADIATION; NEOPLASM; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMINOBENZOATES; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAYTANSINE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGOPEPTIDES; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRASTUZUMAB; TUBULIN MODULATORS;

EID: 84989808578     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13019     Document Type: Article

References (48)

1. Marur, S. & Forastiere, A. A. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. Curr. Opin. Oncol. 222, 206-211 (2010).
2. Laine, A. M., Westover, K. D. & Choy, H. Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer. Semin. Oncol. 41, 57-68 (2014).
3. Cohen, D. J. & Leichman, L. Controversies in the treatment of local and locally advanced gastric and esophageal cancers. J. Clin. Oncol. 33, 1754-1759 (2015).
4. Herskovic, A., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326, 1593-1598 (1992).
5. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348, 1049-1054 (1996).
6. Al-Sarraf, M., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J. Clin. Oncol. 16, 1310-1317 (1998).
7. Morris, M., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 340, 1137-1143 (1999).
8. Furuse, K., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 17, 2692-2699 (1999).
9. Macdonald, J. S., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725-730 (2001).
10. Moding, E. J., Kastan, M. B. & Kirsch, D. G. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat. Rev. Drug Discov. 12, 526-542 (2013).
11. Kesari, S., et al. DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. Future Oncol. 7, 1335-1346 (2011).
12. Liauw, S. L., Connell, P. P. & Weichselbaum, R. R. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci. Transl. Med. 5, 173sr2 (2013).
13. Morris, Z. S. & Harari, P. M. Interaction of radiation therapy with molecular targeted agents. J. Clin. Oncol. 32, 2886-2893 (2014).
14. Dutta, P. R. & Maity, A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 254, 165-177 (2007).
15. Bonner, J. A., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21-28 (2010).
16. Selzer, E. & Kornek, G. Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments. Expert Rev. Clin. Pharmacol. 6, 663-676 (2013).
17. Le, Q. T. & Raben, D. Integrating biologically targeted therapy in head and neck squamous cell carcinomas. Semin. Radiat. Oncol. 19, 1953-1962 (2009).
18. No, M., Choi, E. J. & Kim, I. A. Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol. Ther. 8, 2351-2361 (2009).
19. Zhou, H., et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int. J. Radiat. Oncol. Biol. Phys. 58, 344-352 (2004).
20. Liang, K., et al. Sensitization of breast cancer cells to radiation by trastuzumab. Mol. Cancer Ther. 2, 1113-1120 (2003).
21. Wheeler, D. L., Dunn, E. F. & Harari, P. M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 7, 493-507 (2010).
22. Brand, T. M., et al. AXL mediates resistance to cetuximab therapy. Cancer Res. 74, 5152-5164 (2014).
23. Saki, M., Toulany, M. & Rodemann, H. P. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells. Radiother. Oncol 108, 473-478 (2013).
24. Lavaud, P. & Andre, F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med. 12, 132 (2014).
25. Creedon, H., et al. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer. Biochem. Soc. Trans. 42, 822-830 (2014).
26. Doronina, S. O., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-784 (2003).
27. Mullard, A. Maturing antibody-drug conjugate pipeline hits 30. Nat. Rev. Drug. Discov. 12, 329-332 (2013).
28. Sievers, E. L. & Senter, P. D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29 (2013).
29. Girish, S., et al. Clinical pharmacology of trastuzumab emtansine(T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol. 69, 1229-1240 (2012).
30. Verma, S., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783-1791 (2013).
31. Chen, X., Soma, L. A. & Fromm, J. R. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco. Targets Ther. 7, 45-56 (2013).
32. Okeley, N. M., Alley, S. C. & Senter, P. D. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug. Hematol. Oncol. Clin. North Am. 28, 13-25 (2014).
33. Buckel, L., et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 75, 1376-1387 (2015).
34. Hamblett, K. J., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070 (2004).
35. Lyon, R. P., Meyer, D. L., Setter, J. R. & Senter, P. D. Chapter six-conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. Methods Enzymol. 502, 123-138 (2012).
36. Sanderson, R. J., et al. In vivo drug-linker stability of an anti-CD30 dipeptidelinked auristatin immunoconjugate. Clin Cancer Res. 11, 843-852 (2005).
37. Ang, K. K., et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol. 20, 2940-2950 (2014).
38. Bradley, J. D., et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 16, 187-199 (2015).
39. Ley, J., et al. Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma. Oncology 85, 290-296 (2013).
40. Koutcher, L., et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 81, 915-922 (2011).
41. Lin, S. H., et al. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J. Natl. Cancer Inst. 105, 686-693 (2013).
42. Liu, F. F., et al. Lessons learned from radiation oncology trials. Clin. Cancer Res. 19, 6089-6100 (2013).
43. Swanton, C., Futreal, A. & Eisen, T. Her2-targeted therapies in non-small cell lung cancer. Clin. Cancer Res. 12, 4377s-4383s (2006).
44. Okines, A., Cunningham, D. & Chau, I. Targeting the human EGFR family iesophagogastric cancer. Nat. Rev. Clin. Oncol. 8, 492-503 (2011).
45. Sun, M. M. C., et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem. 165, 1282-1290 (2005).
46. Ayoub, D., et al. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. mAbs 5, 699-710 (2013).
47. Damen, C. W. N., et al. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J. Am. Soc. Mass Spectrom. 20, 2021-2033 (2009).
48. Lyon, R. P., et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat. Biotechnol. 32, 1059-1062 (2014).